Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):


	Three Months Ended March 31,
	2026		2025
Expenses
Manufacturing and process development	$	23,208	$	18,655
Clinical operations and development	14,570		10,026
Research and development personnel cost and other (including stock-based compensation)	9,121		5,096
Research	601		556
Total research and development	47,500		34,333
General and administrative personnel costs (including stock-based compensation)	7,963		4,832
Professional fees	3,560		1,504
Facility costs, IT, office expense and other	1,219		1,119
Total general and administrative expenses	12,742		7,455
Total operating expenses	60,242		41,788
Operating loss	(60,242)		(41,788)
Interest income	4,083		5,014

Total other income	4,083		5,014
Net income before losses	(56,159)		(36,774)
Income tax expense	(52)		(72)
Segment and consolidated net loss	$	(56,211)	$	(36,846)